This story originally ran on April 12.

Kinaxo Biotechnologies said this week it has been granted a European patent covering its proteomics technology.

Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.